133 related articles for article (PubMed ID: 14728852)
1. [Role of positron emission tomography in diagnosis of recurrent ovarian cancer].
Ding XL; Shen K; Lang JH; Wu M; Huang HF; Pan LY; Yang JX
Zhonghua Fu Chan Ke Za Zhi; 2003 Nov; 38(11):667-9. PubMed ID: 14728852
[TBL] [Abstract][Full Text] [Related]
2. [Role of positron emission tomography in detecting recurrent epithelial ovarian carcinoma].
Zhu X; Shen K; Lang J; Wu M; Huang H; Pan L
Zhonghua Fu Chan Ke Za Zhi; 2002 Jun; 37(6):356-8. PubMed ID: 12126572
[TBL] [Abstract][Full Text] [Related]
3. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
4. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer.
Zimny M; Siggelkow W; Schröder W; Nowak B; Biemann S; Rath W; Buell U
Gynecol Oncol; 2001 Nov; 83(2):310-5. PubMed ID: 11606090
[TBL] [Abstract][Full Text] [Related]
5. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
Peng NJ; Liou WS; Liu RS; Hu C; Tsay DG; Liu CB
Cancer Biother Radiopharm; 2011 Apr; 26(2):175-81. PubMed ID: 21510748
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer.
Cho SM; Ha HK; Byun JY; Lee JM; Kim CJ; Nam-Koong SE; Lee JM
AJR Am J Roentgenol; 2002 Aug; 179(2):391-5. PubMed ID: 12130439
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
8. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report.
Yuan CC; Liu RS; Wang PH; Ng HT; Yeh SH
J Reprod Med; 1999 Sep; 44(9):775-8. PubMed ID: 10509300
[TBL] [Abstract][Full Text] [Related]
9. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
[TBL] [Abstract][Full Text] [Related]
10. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
Sheng XG; Zhang XL; Fu Z; Li HQ; Li QS; Ma ZF; Li DP; Chen ZY
Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):460-3. PubMed ID: 17961335
[TBL] [Abstract][Full Text] [Related]
11. [The value of FDG PET/CT, ultrasound and CT in diagnosing recurrent ovarian carcinoma].
Grabiec M; Walentowicz M; Nowicki P
Ginekol Pol; 2006 Oct; 77(10):746-52. PubMed ID: 17219805
[TBL] [Abstract][Full Text] [Related]
12. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.
Nanni C; Rubello D; Farsad M; De Iaco P; Sansovini M; Erba P; Rampin L; Mariani G; Fanti S
Eur J Surg Oncol; 2005 Sep; 31(7):792-7. PubMed ID: 15893908
[TBL] [Abstract][Full Text] [Related]
13. The role of F18-FDG PET/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer.
Amit A; Hodes A; Lavie O; Keidar Z; Matanes E; Lowenstein L
Surg Oncol; 2017 Dec; 26(4):347-351. PubMed ID: 29113651
[TBL] [Abstract][Full Text] [Related]
14. [F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125].
García Velloso MJ; Boán García JF; Villar Luque LM; Aramendía Beitia JM; López García G; Richter Echeverría JA
Rev Esp Med Nucl; 2003; 22(4):217-23. PubMed ID: 12846945
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?
Bilici A; Ustaalioglu BB; Seker M; Canpolat N; Tekinsoy B; Salepci T; Gumus M
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1259-69. PubMed ID: 20309683
[TBL] [Abstract][Full Text] [Related]
16. Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery.
Risum S; Høgdall C; Markova E; Berthelsen AK; Loft A; Jensen F; Høgdall E; Roed H; Engelholm SA
Int J Gynecol Cancer; 2009 May; 19(4):600-4. PubMed ID: 19509556
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review.
Makhija S; Howden N; Edwards R; Kelley J; Townsend DW; Meltzer CC
Gynecol Oncol; 2002 Apr; 85(1):53-8. PubMed ID: 11925120
[TBL] [Abstract][Full Text] [Related]
18. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT.
Kim CK; Park BK; Choi JY; Kim BG; Han H
J Comput Assist Tomogr; 2007; 31(6):868-75. PubMed ID: 18043348
[TBL] [Abstract][Full Text] [Related]
19. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes.
Bristow RE; Giuntoli RL; Pannu HK; Schulick RD; Fishman EK; Wahl RL
Gynecol Oncol; 2005 Nov; 99(2):294-300. PubMed ID: 16051330
[TBL] [Abstract][Full Text] [Related]
20. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
